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Introduction: GeneXpert MTB/RIF is a fully-automated diagnostic molecular test which
simultaneously detects tuberculosis (TB) and rifampicin (RIF) drug resistance. The purpose
of this study is to evaluate the performance of the GeneXpert MTB/RIF test for the detection
of Mycobacterium tuberculosis complex (MTBC) in lymph node specimens and to show the
place of Mycobacterium bovis as a major cause of TB lymphadenitis.
Material and methods: This study was conducted simultaneously in the National Reference
Laboratory for Mycobacteria of Ariana and the Central Laboratory of Sfax, from January to
December 2013. In total, 174 lymph node specimens were processed simultaneously for
Ziehl–Neelsen, auramine and immuno-histochemical staining. Conventional culture on
both Lowenstein–Jensen and liquid medium (Bactec MGIT 960 BD system) and the new
molecular-based GeneXpert MTB/RIF assay system were performed. Positive cultures were
confirmed using molecular identification (Genotype MTBC Hain Lifescience).
Results: Among the 174 samples tested, the GeneXpert detected the DNA of MTBC in 134
samples (77%). Standard bacteriological assays, including AFB microscopy and culture,
were positive, respectively, in 41 (23.6%) and 79 (45.4%) specimens. M. bovis was isolated
in 76% of positive cultures. GeneXpert sensitivity and specificity results were assessed
according to smear and culture results, clinical and histological findings. The sensitivity
and specificity of the Xpert assay were 87.5% (126/144) and 73.3%, respectively.
Conclusion: The implementation of the GeneXpert MTB/RIF assay may dramatically
improve the rapid diagnosis of lymph node TB.
 2015 Asian African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.eumology,
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Tuberculosis (TB) of the lymph nodes (tuberculosis lym-
phadenitis) is one of the most common forms of extrapul-
monary TB whose diagnosis still faces many challenges [1].
In Tunisia, the rate of TB lymphadenitis has increased. In
2012, its frequency was estimated to be 29.3% and in 2014,
35.8% of TB cases [2]. Conventional Mycobacterium tuberculosis
(M. tuberculosis) detection techniques, based on microscopic
examination of Ziehl–Neelsen or auramine-stained speci-
mens and culture, are required for diagnostic confirmation,
but they fail to provide an optimal sensitivity [3]. In recent
times, attention has been devoted to new nucleic acid ampli-
fication diagnostic technologies, owing to their rapidity, sen-
sitivity, and specificity. One of the latest systems, the
GeneXpert MTB/RIF (Xpert) assay, based on nested real-time
PCR and molecular beacon technology, has been shown to
be rapid, with a result for TB and RIF drug resistance under
2 h [4].
The first purpose of the current study was to evaluate the
performance of Xpert MTB/RIF test for the detection of M.
tuberculosis complex (MTBC) in lymph node specimens and
to compare it with conventional methods. This study also
aims to show the place of Mycobacterium bovis (M. bovis) as a
major cause of TB lymphadenitis.Material and methods
Study specimens
This study was conducted simultaneously in the National
Reference Laboratory for Mycobacteria of Ariana and the
Central Laboratory of Sfax, from January to December 2013.
This study was approved by the Ethics Committee of the A.
Mami Hospital of Pneumology, Ariana, Tunisia.
Lymph node specimens (tissues and aspirates) were
prospectively collected from 174 patients in different
Tunisian health centers.
Lymph node TB was suspected on the basis of clinical cri-
teria. Two specimens were collected; the first one was sent to
the bacteriology laboratory and the second to the pathology
laboratory. In the bacteriology lab, the sample was divided
into two parts (biopsies were firstly crushed in a sterile mor-
tar); one was used for the Xpert test and the second one
was tested by direct and concentrated acid fast bacilli (AFB)
microscopy and culture.Mycobacterial culture and smear
All specimens were fully processed by digestion, decontami-
nation and concentration. The N-acetyl-L-cysteine and
sodium hydroxide method (NALC/NaOH) was used for diges-
tion and decontamination. Thereafter, the specimens were
concentrated by centrifugation at 3500g for 15 min and re-
suspended in 1 ml of sterile phosphate buffer (pH = 6.8) [5].
The processed specimen sediment was used to inoculate
two Lowenstein–Jensen (LJ) slants and a Bactec MGIT 960 tube
(mycobacteria growth indicator tube), which were incubated
at 37 C for 12 and 6 weeks, respectively [5,6].Smears of processed sediment were stained with both
Auramine and Ziehl–Neelsen method and examined with flu-
orescent and light microscopy.Identification
Cultures were identified using TB Antigen MPT 64, standard
phenotypic identification tests (Table 1) and molecular meth-
ods [7].SD bioline TB Ag MPT64
All positive cultures were subjected to the immunochromato-
graphic identification test that uses the mouse monoclonal
anti MPT64 [8]. This test can be easily used for rapid identifi-
cation of the MTBC and can differentiate between MTBC and
non-tuberculous mycobacteria (NTM).Phenotypic identification
Phenotypic identification was based on the niacin test, nitrate
reduction test, susceptibility to thiophene-2-carboxylic acid
hydrazide (TCH) and growth on p-nitrobenzoic acid (PNB)
medium (Table 1) [9–11].Molecular identification
For the final identification of MTBC species, the Genotype
MTBC system (Hain Lifescience, Germany) was used. The
assay was performed according to the instructions of the
manufacturer [12].Drug susceptibility testing (DST)
Drug susceptibility testing (DST) of first-line anti-TB drugs
(RIF, isoniazid, ethambutol, pyrazinamide and streptomycin)
was performed with the Bactec MGIT 960 method (MGIT
960; Becton Dickinson Diagnostic Systems).
GeneXpert MTB/RIF procedure
The reagent was added in a 2:1 ratio to decontaminated and
concentrated specimen. The sample container was agitated
twice during a 15-min incubation period at room tempera-
ture. Finally, 2 ml of the inactivated mixture was transferred
to the Xpert test cartridge. Cartridges were inserted into the
GeneXpert device, and the automatically generated results
were read after 90 min [13,14].
Patient categories
Patients were categorized into 4 groups: ‘‘confirmed TB’’
cases (culture positive, smear negative or positive), ‘‘proba-
ble TB’’ cases (culture negative, but showing clinical symp-
toms, smear positive and histology/cytology suggestive of
TB), ‘‘possible TB’’ cases (negative culture, but showing
clinical symptoms, and negative smear and histology/cytol-
ogy suggestive of TB), and ‘‘not TB’’ cases (only clinical
symptoms) [15]. Table 2 represents a detailed algorithm
used for the categorization of patients into different
categories.
Table 2 – Patients categorization.
AFB smear Culture Symptoms Histology/cytology
Confirmed TB +/ + + +/
Probable TB +  + +/
Possible TB   + +
Not TB   + /NP
NP: not performed.
For histology/cytology in case of ‘‘Probable TB’’, a specimen was positive if the presence of caseation necrosis and epithelioid granulomas was
reported.
Table 1 – Phenotypic identification of MTBC.
Niacin Nitrate PNB TCH
M. tuberculosis + + S R
M. bovis   S S
M. africanum V V S V
Non-tuberculous mycobacteria   R S
S: sensitive; R: resistant; V: variable.
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This study included 174 patients. The male-to-female ratio
was 0.47 (56/118). The median age of the patients was
32.3 years (range 3–79 years). All patients were found to be
HIV negative.
AFB smears were positive for 41 cases (23.6%). Scanty AFB
(less than 10 AFB) were observed in 75.6% of smear-positive
specimens. Culture was considered positive if the MGIT tube
and/or LJ media was positive. Contaminated MGIT tube and
LJ media were considered to be negative for the Xpert assay
sensitivity and specificity calculation. Histology/cytology
results were not available for 33 specimens. Overall, 79
(45.4%) of the 174 specimens tested were culture positive.
MTBC was isolated on MGIT and LJ medium in respectively
78 (98.7%) and 40 (50.6%) culture-positive samples. Among
the 174 samples tested, the Xpert detected the DNA of
MTBC in 134 samples (77%). Histopathology was positive for23.60% 
45.40% 
Smear Microscopy Culture H
Fig. 1 – Percentage of positive smear microscopy121 (69.5%) specimens showing the presence of caseation
and epithelioid granulomas (Fig. 1) [14].
In this study, 79 specimens (45.4%) were culture positive
(55 [31.6%] being smear negative and 24 [13.8%] being smear
positive); 22 (12.6%) were ‘‘probable TB’’ cases; 43 (24.7%) were
only histologically/cytologically positive showing necrosis,
caseation, or epithelioid granuloma suggestive of ‘‘possible
TB’’ cases; and 30 (17.2%) patients had no evidence of TB
and were ‘‘not TB’’ cases. Table 3 shows in detail the Xpert
accuracy according to smear and culture results, clinical
and histological findings.
Sensitivity and specificity
Xpert detected MTBC DNA in 75/79 of culture-positive speci-
mens. The sensitivity and specificity of the Xpert assay were
94.9% and 37.9%, respectively, when compared with culture
(Table 4). The sensitivity of the molecular test in smear-69,5% 
77% 
istology/ Pathology Xpert
, culture, histology/cytology and Xpert assay.
Table 3 – Xpert accuracy according to smear and culture results, clinical and histological findings.
AFB smear Culture Symptoms Histology/cytology XP+ XP Total
Confirmed TB + + + +/ 24 0 24
+ + + +/ 51 4 55
Probable TB +  + + 13 2 15
+  +  6 1 7
Possible TB   + + 32 11 43
Not TB   + /NP 8 22 30
Total 134 40 174
NP: not performed.
For histology/cytology a specimen was positive if the presence of caseation necrosis and epithelioid granulomas was reported.
Table 4 – Sensitivities of the Xpert test in comparison with culture method as reference standard.
Method compared to culture % positive specimen (no positive specimen/total No. of specimens)
Xpert sensitivity Smear positive, culture positive 100% (24/24)
Smear negative, culture positive 92.7% (51/55)
All culture positive 94.9% (75/79)
Xpert specificity 37.9% (36/95)
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respectively 100% and 92.7%.
The Xpert test detected TB in 77.6% (45/58) of patients with
negative cultures and positive histology. Furthermore, the
Xpert assay showed 8 positive results in ‘‘not TB’’ cases.
Table 5 shows the sensitivity and specificity of Xpert assay
when compared with smear microscopy, culture results and
histological findings. The sensitivity and specificity were,
respectively, 87.5% and 73.3%. Positive predictive value (ppv)
was 94%, whereas the negative predictive value (npv) was
55%.
Identification and RIF resistance detection
All the strains isolated were identified. M. bovis and M. tuber-
culosis were isolated in 76% (60/79) and 24% (19/79), respec-
tively, (Fig. 2). NTM were not isolated. Positive Ag MPT64
bands were obtained for all MTBC isolates. Strain identifica-
tion was confirmed by the Genotype MTBC assay. All strains
were found to be susceptible to RIF in both Xpert method
and conventional drug susceptibility testing [12,13]. M. bovis
strains showed resistance to pyrazinamide. No additional
resistance was found to anti-tuberculous drugs.Table 5 – Sensitivity and specificity of Xpert in comparison with
histologicala findings.
TB+b TBc Sensitivity
Xpert+ 126 8 87.5% (126/144)
Xpert 18 22
a For histology/cytology, a specimen was positive if the presence of case
b Confirmed, probable or possible TB.
c Smear microscopy () and culture () and histology/cytology ().Discussion
In 2012, the incidence of TB in Tunisia was 31/100,000 and the
incidence of lymph node TB was 4.9/100,000 [16]. In 2014,
58.74% of TB cases were extrapulmonary [2]. Tuberculous
lymphadenitis accounted for 29.3% in 2012 and increased to
35.8% in 2014 [2]. Improving diagnosis tools in Tunisia seems
to be necessary. Although different laboratory techniques are
available, they suffer from sub-optimal sensitivity and/or
specificity, and diagnosis of lymph node TB remains difficult.
Microscopy using Ziehl–Neelsen or auramine staining pro-
cedure is easy, rapid and cheap. The sensitivity varies
depending on the source of the sample. It was low (23.6%)
in this study. Scanty AFB were observed in 75.6% of smear-
positive microscopy. In India, the sensitivity ranges from
46% to 78% [17]. This weak sensitivity can be explained by
the paucibacillary nature of specimens.
Culture is the gold standard for TB diagnosis. It is time-
consuming, requires biosafety measures and needs trained
laboratory personnel [18]. MGIT has improved lymph node
TB diagnosis. Indeed, it gave a higher yield of mycobacteria
and faster results than LJ medium [6]. Although solid and liq-
uid media were combined, culture shows a low sensitivity insmear microscopy and culture results, clinical and
Specificity VPP VPN
73.3% (22/30) 94% (126/134) 55% (22/40)
ation necrosis with or without epithelioid granulomas was reported.
M.bovis 
76% 
M.tuberculosis 
24% 
Fig. 2 – Distribution of MTBC strains.
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were 45.4% in this study. This may be attributed to the uneven
bacilli distribution and the loss of the low number of viable
bacilli during NALC-NaOH processing [6,18].
The World Health Organization (WHO) has endorsed the
Xpert MTB/RIF assay as a replacement for sputum smear
microscopy. For the diagnosis of patients presumed to have
extrapulmonary TB, Xpert MTB/RIF may be used as a replace-
ment test for usual practice (including conventional micro-
scopy, culture, and/or histopathology) for testing of specific
non-respiratory specimens (lymph nodes and other tissues)
[19].
This multifunctional diagnostic platform is an automated,
closed system that performs real-time PCR and can be used
by operators with minimal technical expertise, enabling for
the diagnosis of TB and simultaneous assessment of RIF resis-
tance to be completed within 2 h [20].
In the present study, a high sensitivity of the Xpert test for
the diagnosis of lymph node TB reported. In fact, the assay
detects 94.93% (75/79) of all ‘‘confirmed TB’’ cases, including
92.72% (51/55) of smear-negative TB cases. It was also
observed that the Xpert assay detects TB in 75.47% (40/53) of
the samples from ‘‘probable TB’’ cases (Table 3). The Xpert
sensitivity of ‘‘confirmed TB’’ was higher than that reported
by Vadwai et al. (83%), whereas the sensitivity of ‘‘probable
TB’’ was found to be lower (80%) [15].
The Xpert was also positive in 26.67% (8/30) of ‘‘not TB’’
samples (Tables 3 and 4). Out of these 8 specimens, 1 was
cytologically negative, and for 7 specimens, histology/cytol-
ogy was not performed. These 8 specimens were considered
cytologically negative. This can explain the lack of specificity
(73.33% [22/30]) reported in the study. If specimens not tested
for cytology were excluded, the Xpert specificity would be
dramatically improved to 95.65% (22/23). The lack of speci-
ficity can be also attributed to patients who were under anti-
tubercular treatment when enrolled in the study. This data
was not taken into account.
Few studies reported bacteriological identification of
extrapulmonary and lymph node TB in Tunisia. The exactcontribution of M. bovis to the human TB remains unknown.
This study shows that M. bovis was the dominant causative
agent of TB lymphadenitis (76%). In contrast, most studies
report M. tuberculosis as the main etiological agent of lymph
node TB [21,22]. Historically, M. bovis was the common cause
of TB lymphadenitis, but pasteurization and bovine TB pro-
grams have virtually eliminated this source of human infec-
tion in developed countries; risk remains with the
consumption of unpasteurized milk and dairy products [23].
These products are widely consumed in Tunisia where bovine
TB is enzootic [24–26]. A national program for bovine TB con-
trol has been implemented since 1984. Nevertheless, the dis-
ease continues to be prevalent, mainly in the private sector
where predominant small cattle herds make the veterinary
control a challenge [24,26].
Finally, because of the absence of RIF-resistant strains, the
performance of Xpert assay for RIF-resistance detection can-
not be assessed.
Conclusion
Rapid TB tests may be the key to worldwide TB control strate-
gies. The high sensitivity and specificity, coupled with its
speed and simplicity, make the GeneXpert MTB/RIF the most
useful tool in the rapid diagnosis of lymph node TB. This rapid
TB diagnostic test may complement usual methods (conven-
tional microscopy, culture and histopathology).
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